Skip to Content

Olopatadine nasal Pregnancy and Breastfeeding Warnings

Olopatadine nasal is also known as: Patanase

Medically reviewed on Jul 9, 2018

Olopatadine nasal Pregnancy Warnings

Animal reproductive studies have revealed evidence of treatment-related effects on fetuses/pups. Following high oral doses in rat and rabbits, there was evidence of a decrease in the number of live fetuses, reduced viability, and decreased body weights. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.

US FDA pregnancy category: C

See references

Olopatadine nasal Breastfeeding Warnings

This drug has been found in the milk of nursing rats following oral administration.

This drug should be used by nursing mothers only if the potential benefit to the mother outweighs the potential risk to the infant

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Patanase (olopatadine nasal)." Alcon Laboratories Inc, Fort Worth, TX.

References for breastfeeding information

  1. "Product Information. Patanase (olopatadine nasal)." Alcon Laboratories Inc, Fort Worth, TX.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide